Stay updated with breaking news from Debbie Etchison. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with... | March 30, 2023
SCYNEXIS, Inc. (NASDAQ:NASDAQ:SCYX) Q3 2022 Results Conference Call November 9, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr.
Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response or no disease progression . Data from the ongoing Phase... | September 8, 2022
15.08.2022 - BREXAFEMME (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1.3 million in Q2 2022, compared to $0.7 million in Q1. SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand ...